AbCellera BiologicsABCL -6.72%59 Debt-to-Equity is 0.15 as of Mar. 2026, which is 114% above its 10-year median of 0.07. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.38 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, AbCellera Biologics ranks better than 52.69% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for AbCellera Biologics's Debt-to-Equity or its related term are showing as below:
ABCL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 0.67
Current: 0.15
During the past 8 years, the highest Debt-to-Equity Ratio of AbCellera Biologics was 0.67. The lowest was 0.01. And the median was 0.07.
ABCL's Debt-to-Equity is ranked better than 52.69% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs ABCL: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
AbCellera Biologics Debt-to-Equity Related Terms
AbCellera Biologics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs AGIO, KOD, IMNM: Debt-to-Equity Comparison
For the Biotechnology subindustry, AbCellera Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Debt-to-Equity of 0.15 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AbCellera Biologics and its competitors. This is 114% above median its historical median of 0.07. Over the past decade, AbCellera Biologics' Debt-to-Equity has ranged from 0.01 to 0.67. According to the industry distribution chart, AbCellera Biologics ranks #457 out of 966 companies in the Biotechnology industry, placing it in the top 47.3%.
Is AbCellera Biologics' Debt-to-Equity too high?
AbCellera Biologics' current Debt-to-Equity of 0.15 is 114% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.67. The Biotechnology industry median Debt-to-Equity is 0.16. AbCellera Biologics' value of 0.15 is 6.3% below this industry median. Based on the distribution chart, AbCellera Biologics ranks #457 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Debt-to-Equity compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #457 out of 966 companies for Debt-to-Equity. This puts AbCellera Biologics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. AbCellera Biologics' value of 0.15 is 6.3% below this benchmark. Historically, AbCellera Biologics' own Debt-to-Equity has ranged from 0.01 to 0.67 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.16, AbCellera Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Debt-to-Equity of 0.15 is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Debt-to-Equity is 0.15, which is 114% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $6.79 — trading 26.2% above its estimated fair value. The current Debt-to-Equity is 0.15, which is 114% above median its 10-year median of 0.07 and 6.3% below the Biotechnology industry median of 0.16. AbCellera Biologics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Debt-to-Equity is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $6.79 is trading 26.2% above its estimated GF Value™ of $5.38.
GuruFocus considers AbCellera Biologics to be Modestly Overvalued.
Key valuation signals for ABCL:
Debt-to-Equity: 0.15 (114% above median its 10-year median of 0.07)
GF Value™: $5.38 vs. price of $6.79 (26.2% above fair value)
Industry Position: 6.3% below the Biotechnology median (#457 of 966)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
